KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Assets Average (2016 - 2026)

Biocryst Pharmaceuticals filings provide 15 years of Assets Average readings, the most recent being $480.3 million for Q4 2025.

  • On a quarterly basis, Assets Average fell 2.15% to $480.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $480.3 million, a 2.15% decrease, with the full-year FY2025 number at $502.3 million, changed 0.28% from a year prior.
  • Assets Average hit $480.3 million in Q4 2025 for Biocryst Pharmaceuticals, up from $451.8 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $557.9 million in Q1 2022 to a low of $271.5 million in Q3 2021.
  • Median Assets Average over the past 5 years was $488.0 million (2024), compared with a mean of $468.6 million.
  • Biggest five-year swings in Assets Average: soared 98.53% in 2021 and later fell 9.55% in 2024.
  • Biocryst Pharmaceuticals' Assets Average stood at $427.0 million in 2021, then rose by 29.83% to $554.3 million in 2022, then fell by 6.2% to $519.9 million in 2023, then decreased by 5.6% to $490.8 million in 2024, then dropped by 2.15% to $480.3 million in 2025.
  • The last three reported values for Assets Average were $480.3 million (Q4 2025), $451.8 million (Q3 2025), and $468.6 million (Q2 2025) per Business Quant data.